Compare Moderna, Inc. (MRNA) vs Koninklijke Philips NV (PHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Koninklijke Philips NV — how do they compare? Moderna, Inc. trades at $59.66 (market cap $23.60B), while Koninklijke Philips NV trades at $26.77 (market cap $26.19B). The key difference: Moderna, Inc. and Koninklijke Philips NV are close in size by market cap, and Koninklijke Philips NV pays a 3.79% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | PHG | |
|---|---|---|
Market Cap | $23.60B | $26.19B |
Sector | Health | Health |
52-Week High | $81.80 | $32.91 |
52-Week Low | $22.36 | $24.54 |
Enterprise Value | $19.70B | $32.46B |
Dividend Yield | — | 3.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $59.66, down 3.49% in the last session amid broader biotech volatility. The stock shows a mixed technical picture with bullish overall signals but bearish moving averages. Fundamentally, revenue has declined from pandemic peaks to $1.92B in 2025, with net losses widening to -$2.82B. Recent positive developments include an EU RSV vaccine contract and progress in cancer immunotherapy trials, with Q2 2026 earnings due July 31.
Outlook remains speculative as Moderna transitions beyond COVID-19 vaccines. Opportunities lie in its expanding pipeline in oncology and flu vaccines, but risks include sustained losses, competitive pressure, and execution hurdles. Analyst consensus is cautious with a $49 price target below current levels, reflecting uncertainty over profitability timeline.
PHG trades at $26.58, down 1.37% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported net income of $895 million in 2025, a significant recovery from prior losses, with a net margin of 5.5%. Recent FDA clearances for medical devices and AI integrations highlight ongoing innovation. Cash flow from operations remains positive at $1.17 billion for 2025, though net cash flow declined to $403 million.
The outlook is mixed: analyst consensus is neutral with 59% hold ratings, reflecting caution despite recent profitability improvements. Key risks include high debt levels, with debt-to-asset ratio at 25.44% in 2025, and competitive pressures in health technology. Upside potential hinges on execution of AI-driven growth initiatives and margin expansion, as noted in Seeking Alpha analysis on 2026-05-20.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Koninklijke Philips NV
Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →
